Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Kamangar F, Nasrollahzadeh D, Safiri S, et al. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):582–597. doi:10.1016/s2468-1253(20)30007-832246941
   PubMed Web of Science ®Google Scholar
• Leng X-F, Daiko H, Han Y-T, Mao Y-S. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma. Ann N Y Acad Sci. 2020;1482(1):213–224. doi:10.1111/nyas.1450833067818
   PubMed Web of Science ®Google Scholar
• Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;CD008107(5). doi:10.1002/14651858.CD008107.pub2
   Web of Science ®Google Scholar
• Donohoe CL, McGillycuddy E, Reynolds JV. Long-term health-related quality of life for disease-free esophageal cancer patients. World J Surg. 2011;35(8):1853–1860. doi:10.1007/s00268-011-1123-621553202
   PubMed Web of Science ®Google Scholar
• Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23(5):1095–1103. doi:10.1093/annonc/mdr43322003242
   PubMed Web of Science ®Google Scholar
• Steffen T, Dietrich D, Schnider A, et al. Recurrence patterns and long-term results after induction chemotherapy, chemoradiotherapy, and curative surgery in patients with locally advanced Esophageal cancer. Ann Surg. 2019;269(1):83–87. doi:10.1097/sla.000000000000243528742685
   PubMed Web of Science ®Google Scholar
• Yamashita K, Hosoda K, Moriya H, et al. Prognostic advantage of docetaxel/cisplatin/5-fluorouracil neoadjuvant chemotherapy in clinical stage II/III Esophageal squamous cell carcinoma due to excellent control of preoperative disease and postoperative lymph node recurrence. Oncology. 2017;92(4):221–228. doi:10.1159/00045512828110330
   PubMed Web of Science ®Google Scholar
• Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098. doi:10.1016/S1470-2045(15)00040-626254683
   PubMed Web of Science ®Google Scholar
• Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19(7):965–974. doi:10.1016/S1470-2045(18)30201-829861116
   PubMed Web of Science ®Google Scholar
• Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78(4):1152–1160. doi:10.1016/j.athoracsur.2004.04.04615464463
   PubMed Web of Science ®Google Scholar
• Li S-H, Rau K-M, Lu H-I, et al. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3–4 oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 2012;42(6):958–964. doi:10.1093/ejcts/ezs13622466694
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084. doi:10.1056/NEJMoa111208822646630
   PubMed Web of Science ®Google Scholar
• de Gouw D, Klarenbeek BR, Driessen M, et al. Detecting pathological complete response in Esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis. J Thorac Oncol. 2019;14(7):1156–1171. doi:10.1016/j.jtho.2019.04.00430999111
   PubMed Web of Science ®Google Scholar
• Borggreve AS, Goense L, van Rossum PSN, et al. Preoperative prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal cancer using 18F-FDG PET/CT and DW-MRI: a Prospective Multicenter Study. Int J Radiat Oncol Biol Phys. 2020;106(5):998–1009. doi:10.1016/j.ijrobp.2019.12.03831987972
   PubMed Web of Science ®Google Scholar
• Djuric-Stefanovic A, Jankovic A, Saponjski D, et al. Analyzing the post-contrast attenuation of the esophageal wall on routine contrast-enhanced MDCT examination can improve the diagnostic accuracy in response evaluation of the squamous cell esophageal carcinoma to neoadjuvant chemoradiotherapy in comparison with the esophageal wall thickness. Abdom Radiol. 2019;44(5):1722–1733. doi:10.1007/s00261-019-01911-w
   PubMed Web of Science ®Google Scholar
• Barbetta A, Sihag S, Nobel T, et al. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery. J Thorac Cardiovasc Surg. 2019;157(3):1249–1259 e1245. doi:10.1016/j.jtcvs.2018.09.13630655068
   PubMed Web of Science ®Google Scholar
• Heneghan HM, Donohoe C, Elliot J, et al. Can CT-PET and endoscopic assessment post-neoadjuvant chemoradiotherapy predict residual disease in Esophageal cancer? Ann Surg. 2016;264(5):831–838. doi:10.1097/SLA.000000000000190227741010
   PubMed Web of Science ®Google Scholar
• Tomasello G, Petrelli F, Ghidini M, et al. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: a meta-analysis of 17 published studies. Eur J Surg Oncol. 2017;43(9):1607–1616. doi:10.1016/j.ejso.2017.03.00128347525
   PubMed Web of Science ®Google Scholar
• Thomas M, Borggreve AS, van Rossum PSN, et al. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis. Acta Oncol. 2019;58(10):1358–1365. doi:10.1080/0284186X.2019.164643231432736
   PubMed Web of Science ®Google Scholar
• Haisley KR, Laird AE, Nabavizadeh N, et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with Esophageal cancer. JAMA Surgery. 2016;151(11):e162743. doi:10.1001/jamasurg.2016.274327627765
   PubMed Web of Science ®Google Scholar
• van der Bogt R, Noordman BJ, Krishnadath KK, et al. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. Endoscopy. 2019;51(4):326–332. doi:10.1055/a-0795-322030497088
   PubMed Web of Science ®Google Scholar
• van Rossum PSN, Goense L, Meziani J, et al. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis. Gastrointest Endosc. 2016;83(5):866–879. doi:10.1016/j.gie.2015.11.02626632523
   PubMed Web of Science ®Google Scholar
• Wang L, Liu L, Han C, et al. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy. Radiother Oncol. 2016;121(2):246–251. doi:10.1016/j.radonc.2016.10.02127838148
   PubMed Web of Science ®Google Scholar
• Little AG, Lerut AE, Harpole DH, et al. The society of thoracic surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. Ann Thorac Surg. 2014;98(5):1880–1885. doi:10.1016/j.athoracsur.2014.07.06925262396
   PubMed Web of Science ®Google Scholar
• Tu -C-C, Hsu P-K, Chien L-I, et al. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery. BMC Cancer. 2017;17(1):62. doi:10.1186/s12885-017-3063-528103913
   PubMed Web of Science ®Google Scholar
• Lagarde SM, Phillips AW, Navidi M, et al. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. Br J Cancer. 2015;113(10):1427–1433. doi:10.1038/bjc.2015.35426554656
   PubMed Web of Science ®Google Scholar
• Gu Y-M, Yang Y-S, Hu W-P, et al. Prognostic value of lymphovascular invasion in patients with esophageal squamous cell carcinoma. Ann Transl Med. 2019;7(12):256. doi:10.21037/atm.2019.05.2331355223
   PubMed Web of Science ®Google Scholar